India has the largest number of FDA-certified pharmaceutical factories outside the United States, and all Indian generic drugs are in strict accordance with FDA standards, directly imitating the generic drugs produced by the original research drugs, which is a good drug with good quality and low price.
Indian pharmaceutical companies are protected by the national government. In order to reduce the price of drugs, the Indian government can successfully manufacture generic drugs, and only support the patent of drugs after 1995, and does not support the application for patents of existing drugs or derivatives.
For example, the newly developed version of Gleevec is considered as a derivative drug, which lacks innovation and should not be patented. Therefore, there is no patent protection in India, and Indian pharmaceutical companies can copy it at will.
At the same time, India also has a compulsory patent licensing system, which can ignore some drug patents and force the production of generic drugs.